Antitumor effect of E7080 in oral carcinoma xenograft model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Oral squamous cell carcinoma (OSCC) is difficult to treat, and advanced OSCC is particularly difficult as surgical treatment has an adverse effect on the patient’s quality of life. Current trials aim to identify a molecular target for managing OSCC to provide more selective treatment strategies. Angiogenesis and lymphangiogenesis are well-known mechanisms related to tumor growth and metastasis; hence, several studies focus on the identification of drugs that can inhibit angiogenesis and lymphangiogenesis in intra-tumoral or peritumoral areas. The purpose of this study was to evaluate the anti-tumor effect of E7080 in an OSCC nude mouse model by analyzing the tumor growth patterns. We evaluated the changes in CD31 and LYVE-1 expression in the tumor mass after oral administration of E7080. E7080 is a multiple tyrosine kinase inhibitor with anti-angiogenic and anti-lymphangiogenic effects. CD31 is an angiogenesis marker, whereas LYVE-1 is lymphangiogenesis marker. We measured staining densities by immunohistochemistry, using antibodies against CD31 and LYVE-1 to evaluate changes in angiogenesis and lymphangiogenesis, respectively, after oral administration of E7080 in a murine model of OSCC. Two human oral squamous cell lines, KB and SCC-9, were used in the study. Injection of OSCC tumor cells into the submandibular gland resulted in successful tumor growth in all animals. The treated groups showed higher body weights than the un-treated groups; the un-treated groups showed more rapid tumor growth than the treated groups in both SCC9 and KB subgroups; and the tumors were larger in the un-treated groups compared with those in the treated groups for both KB and SCC9 subgroups. Cervical lymph node metastasis was absent in the treatment group. Lung metastasis was absent in the treated KB subgroup, and the treated SCC9 subgroup showed one lung metastasis. The CD31 and LYVE-1 staining intensities were less in the E7080 treatment groups, but withoutstatistical significance (P>0.05). In conclusion, OSCC tumor model is a reproducible method for cancer research, and E7080 is a potential candidate for the selective management of human OSCC.
Abstract
Oral squamous cell carcinoma (OSCC) is difficult to treat, and advanced OSCC is particularly difficult as surgical treatment has an adverse effect on the patient’s quality of life. Current trials aim to identify a molecular target for managing OSCC to provide more selective treatment strategies. Angiogenesis and lymphangiogenesis are well-known mechanisms related to tumor growth and metastasis; hence, several studies focus on the identification of drugs that can inhibit angiogenesis and lymphangiogenesis in intra-tumoral or peritumoral areas. The purpose of this study was to evaluate the anti-tumor effect of E7080 in an OSCC nude mouse model by analyzing the tumor growth patterns. We evaluated the changes in CD31 and LYVE-1 expression in the tumor mass after oral administration of E7080. E7080 is a multiple tyrosine kinase inhibitor with anti-angiogenic and anti-lymphangiogenic effects. CD31 is an angiogenesis marker, whereas LYVE-1 is lymphangiogenesis marker. We measured staining densities by immunohistochemistry, using antibodies against CD31 and LYVE-1 to evaluate changes in angiogenesis and lymphangiogenesis, respectively, after oral administration of E7080 in a murine model of OSCC. Two human oral squamous cell lines, KB and SCC-9, were used in the study. Injection of OSCC tumor cells into the submandibular gland resulted in successful tumor growth in all animals. The treated groups showed higher body weights than the un-treated groups; the un-treated groups showed more rapid tumor growth than the treated groups in both SCC9 and KB subgroups; and the tumors were larger in the un-treated groups compared with those in the treated groups for both KB and SCC9 subgroups. Cervical lymph node metastasis was absent in the treatment group. Lung metastasis was absent in the treated KB subgroup, and the treated SCC9 subgroup showed one lung metastasis. The CD31 and LYVE-1 staining intensities were less in the E7080 treatment groups, but withoutstatistical significance (P>0.05). In conclusion, OSCC tumor model is a reproducible method for cancer research, and E7080 is a potential candidate for the selective management of human OSCC.
참고문헌 (24)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Omura K, "Current status of oral cancer treatment strategies : surgical treatments for oral squamous cell carcinoma", Int J Clin Oncol, 19, pp.423~430 (2014)
- Carvalho AL, "Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach", Oral Dis, 9, pp.112~118 (2003)
- Petrelli F, "Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer : a systematic review and meta-analysis of published studies", Oral Oncol, 50, pp.1041~1048 (2014)
- Folkman J, "The role of angiogenesis in tumor growth", Semin Cancer Biol, 3, pp.65~71 (1992)
- Folkman J, "Role of angiogenesis in tumor growth and metastasis", Semin Oncol, 29, pp.15~18 (2002)
- Carmeliet P, "Angiogenesis in cancer and other diseases", Nature, 407, pp.249~257 (2000)
- Dvorak HF, "Vascular permeability factor", vascular endothelial growth factor : a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, 2002, pp.20, 4368~4380
- Kerbel R, "Clinical translation of angiogenesis inhibitors", Nat Rev Cancer, 2, pp.727~739 (2002)
- Uzzan B, "Microvessel density as a prognostic factor in women with breast cancer : a systemic review of the literature and meta-analysis", Cancer Res, 64, pp.2941~2955 (2004)
- Paduch R, "The role of lymphangiogenesis and angiogenesis in tumor metastasis", Cell Oncol, 28, pp.1~14 (2016)
- Bono P, "High LYVE-1–positive lymphatic vessel numbers are associated with poor outcome in breast cancer", Clin Cancer Res, 10, pp.7144~7149 (2004)
- Mumprecht V, "In vivo Imaging of inflammation-and tumorinduced lymph node lymphangiogenesis by immuno–positron emission tomography", Cancer Res, 70, pp.8842~8851 (2010)
- Matsui J, "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor(VEGF-R)2 and VEGF-R3 kinase", Clin Cancer Res, 14, pp.5459~5465 (2008)
- Matsui J, "E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition", Int J Cancer, 122, pp.664~671 (2008)
- Bruheim S, "Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts", Int J Cancer, 129, pp.742~750 (2011)
- Ikuta K, "E7080, a multi–tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles", Clin Cancer Res, 15, pp.7229~7237 (2009)
- Matsui J, "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor(VEGF-R)2 and VEGF-R3 kinase", Clin Cancer Res, 14, pp.5459~5465 (2008)
- Ogino H, "E7080suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor", Mol Cancer Ther, 10, pp.1218~1228 (2011)
- Park YW, "Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice", Oncol Rep, 23, pp.701~708 (2010)
- 김찬우, "구강암 세포에서 혈관내피성장인자 수용체-3 억제제의 항종양 효과", Maxillofacial Plastic Reconstructive Surgery, 34(4), pp.239~245 (2012), 대한악안면성형재건외과학회
- Jain RK, "Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy", Science, 307, pp.58~62 (2005)
- Jian RK, "Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis : insights from a mathematical model", Cancer Res, 67, pp.2729~2735 (2007)
- Peterson JK, "Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development", Eur J Cancer, 40, pp.837~844 (2004)